A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study.
Evelien MoorkensArnold G VultoJames KentLindsay McClureRichard BolderoThibault VanhoveSteven R A SimoensIsabelle HuysPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)
This study has shown that the savings potential drives biosimilar use. Regions with a proactive attitude, good stakeholder relationships, and clinician engagement were identified as early adopters.